Orum Therapeutics, Inc.
475830.KQ
Get informed when a big investor buys or sells
+ FollowMarket Cap$409.15B
Close$
Share Statistics
| Market cap | $409.15 Billion |
|---|---|
| Enterprise Value | $392.91 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2017 |
| Beta | 0.46 |
| Outstanding Shares | 21,573,966 |
Return
| Return on Equity | 9.95% |
|---|---|
| Return on Assets | 6.34% |
| Return on Invested Capital | 8.67% |
Valuation & Multiples
| P/E Ratio | 22.34 |
|---|---|
| PEG | -1.25 |
| Price to Sales | 19270.0 |
| Price to Book Ratio | 2.24 |
| Enterprise Value to Revenue | 9688.76 |
| Enterprise Value to EBIT | 21.57 |
| Enterprise Value to Net Income | 21 |
| Total Debt to Enterprise | 0.25 |
| Debt to Equity | 0.52 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Orum Therapeutics, Inc.
21 employees
CEO: Sung-Joo Lee Orum Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery and development of novel therapeutic solutions for both cancer and immune system conditions. The firm specializes in creating degrader-antibody conjugates,...